Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mazorelvimab
- Development stage
- Unknown
- Lead developer
- Xingmeng Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Infiltration
01
Overview
Mazorelvimab is a humanized IgG1κ monoclonal antibody that targets the rabies virus glycoprotein (RABV-G), binding to highly discontinuous, conserved residues outside of antigenic site III. It is used as part of a 1:1 mixture with zamerovimab (CTB011) in the product known as SYN-023 or 克瑞毕, designed for post-exposure prophylaxis against rabies virus infection. The combination therapy leverages two antibodies with non-overlapping epitopes to broaden neutralization coverage against global rabies strains. Mazorelvimab and its combination have demonstrated good efficacy and safety in clinical trials, including use in patients with grade III rabies exposure[1][4][5][8].
- Brand names
- 克瑞毕SYN-023SYN023SYN 023
- Other names
- SYN-023SYN023SYN 023
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on Mazorelvimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mazorelvimab.